科济药业-B(02171.HK) 公布,珠海软银欣创旗下管理的基金(投资者)以现金对价8,000万人民币认购优恺泽增资后注册资本8%。完成后,公司于优恺泽权益将由100%降至92%,后者是一家在内地专注于利用通用型CAR-T细胞疗法治疗血液瘤的新药研发公司。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.